These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 28445498)

  • 1. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    Schneider R; Bellenberg B; Hoepner R; Kolb EM; Ellrichmann G; Haghikia A; Gold R; Lukas C
    PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
    J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA; Puccio LM; Brydon EW
    J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into Metabolic
    Schneider R; Bellenberg B; Hoepner R; Ellrichmann G; Gold R; Lukas C
    Front Neurol; 2017; 8():454. PubMed ID: 28928709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH; Huang D
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
    Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy.
    Chang L; Ernst T; Tornatore C; Aronow H; Melchor R; Walot I; Singer E; Cornford M
    Neurology; 1997 Apr; 48(4):836-45. PubMed ID: 9109865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
    J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV.
    Simone IL; Federico F; Tortorella C; Andreula CF; Zimatore GB; Giannini P; Angarano G; Lucivero V; Picciola P; Carrara D; Bellacosa A; Livrea P
    J Neurol Neurosurg Psychiatry; 1998 Apr; 64(4):516-23. PubMed ID: 9576546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
    Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
    J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
    Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.